Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells $1,149,737.50 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 58,750 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $19.57, for a total transaction of $1,149,737.50. Following the completion of the sale, the chief operating officer now owns 630,166 shares of the company’s stock, valued at approximately $12,332,348.62. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Melissa Baird also recently made the following trade(s):

• On Wednesday, September 4th, Melissa Baird sold 11,749 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total transaction of $172,122.85.
• On Tuesday, August 6th, Melissa Baird sold 16,784 shares of Hims & Hers Health stock. The shares were sold at an average price of $17.00, for a total transaction of $285,328.00.

Hims & Hers Health Trading Down 3.4 %

Shares of Hims & Hers Health stock traded down $0.67 during trading on Tuesday, hitting $18.77. 19,402,621 shares of the stock traded hands, compared to its average volume of 7,941,402. The firm has a market cap of $4.03 billion, a P/E ratio of -1,944.00 and a beta of 1.06. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $25.74. The stock’s fifty day simple moving average is $16.50 and its 200 day simple moving average is $17.31.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period in the previous year, the company posted ($0.03) earnings per share. The firm’s revenue was up 51.8% on a year-over-year basis. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently bought and sold shares of HIMS. Renaissance Technologies LLC increased its stake in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after acquiring an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. M&G Plc acquired a new stake in shares of Hims & Hers Health in the 1st quarter worth $8,232,000. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after acquiring an additional 328,142 shares during the last quarter. Finally, State of Michigan Retirement System increased its stake in shares of Hims & Hers Health by 177.8% in the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after acquiring an additional 320,000 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. TD Cowen raised their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Truist Financial boosted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Bank of America reduced their price objective on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, September 13th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.